In This Article:
German pharma company Merck is buying US biotech SpringWorks Therapeutics for $3.9B. SpringWorks makes medicines for cancer and rare diseases and is expected to give a boost to Merck's health-care division. Belen Garijo, Merck KGaA CEO joined Bloomberg Open Interest to talk about the deal.